High-dose heparin suppresses platelet alpha granule secretion

Area of Science:

• Cardiovascular Biology
• Hematology
• Pharmacology

Background:

• Platelet degranulation contributes to arterial thrombosis, intimal hyperplasia, and atherogenesis.
• Previous studies on heparin's effects on platelet function yielded contradictory results using platelet aggregometry, which cannot assess degranulation.
• Flow cytometry enables precise quantification of platelet degranulation via GMP-140 (glycoprotein-140) expression on the platelet surface.

Purpose of the Study:

• To investigate the effect of varying heparin concentrations on platelet degranulation.
• To determine if heparin's antiplatelet activity is linked to its anticoagulant properties.

Main Methods:

• Whole blood anticoagulated with sodium citrate was treated with increasing heparin concentrations.
• Platelets were activated using agonists like a thromboxane A2 analog (U46619), adenosine diphosphate, epinephrine, and thrombin.
• Platelet degranulation was quantified using flow cytometry by measuring GMP-140 surface expression (S12 antibody binding).

Main Results:

• Heparin suppressed platelet alpha granule release induced by U46619, ADP/epinephrine, and thrombin at concentrations up to 100 units/ml.
• This inhibition of degranulation occurred in both whole blood and washed platelets.
• Heparin added post-activation did not affect GMP-140 binding, indicating its effect is on the degranulation process itself.

Conclusions:

• High concentrations of heparin are potent inhibitors of platelet degranulation.
• This antiplatelet effect is independent of heparin's anticoagulant activity via the coagulation cascade.
• Future research may focus on heparin fractions to develop agents that selectively inhibit platelet degranulation without causing anticoagulation.